Moonwalk Biosciences Raises $70M Series B for Adipose-Targeted Obesity Drug
Moonwalk Biosciences closed a $70 million Series B funding round to advance its lead adipose-targeted RNA interference candidate, MW101, into first-in-human clinical trials by late 2027. Led by Alpha Wave ... Read More